
- /
- Supported exchanges
- / US
- / BIOVF.PINK
Swedish Orphan Biovitrum AB (publ) (BIOVF PINK) stock market data APIs
Swedish Orphan Biovitrum AB (publ) Financial Data Overview
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Swedish Orphan Biovitrum AB (publ) data using free add-ons & libraries
Get Swedish Orphan Biovitrum AB (publ) Fundamental Data
Swedish Orphan Biovitrum AB (publ) Fundamental data includes:
- Net Revenue: 26 236 M
- EBITDA: 9 292 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-16
- EPS/Forecast: 1.62
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Swedish Orphan Biovitrum AB (publ) News

Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook
* Swedish Orphan Biovitrum AB press release [https://www.sobi.com/en/financial-reports/sobi-publishes-q2-2025-report-continued-strong-portfolio-and-pipeline-momentum] (OTCPK:BIOVF [https://seekingal...


Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased 13 per cent,...

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the purpose of ensuring that the company can fulfil ...

Invitation: Sobi's Q2 report
Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST. STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference c...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.